Regulatory and Safety: Obesity Drugs - Applied Clinical Trials

home: : subscribe: :

Facebook

LinkedIn : : about us: :

rss feeds/xml

Search
Suppliers
Careers

About Search

Email|Print|

|Save|License

Diabetes & Obesity Series

Safety and Regulatory Aspects of Obesity Drugs

Subscribe to RSS feed of this series

Dr. David Orloff
Executive Director of Regulatory Affairs
Medpace

Dr. Orloff discusses the current and potential future regulatory issues for obesity and diabetes drugs, how FDA and industry is moving toward levels of safety for these drug classes.

Others in the Series

Diabetes Resources

Articles, Multimedia

Associations and Societies

Clinical Trials

Obesity Resources

Articles, Multimedia

Associations and Societies

Clinical Trials

PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook 2009/2010, click here to purchase! Free white paper on Pharsight® on-demand clinical data repository - manage your data for submission, due diligence and out-licensing. Click here! Pharmaceutical & Biotech conferences covering the entire pipeline from discovery to development, trials and marketing	Free white paper on SAS® Clinical Data Integration. Click here Secure clinical research grants-register for TrialWatch for Sites, CenterWatch's new complimentary grant notification service!